Evidence map›Paper›PMID 42649211›Full record

ArticleNature communications2026

Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer.

Krishnan K Mahadevan, Ana S Maldonado, Bingrui Li, Aaron A Bickert, Adrian Kacperczyk-Perdyan, Shreyasee V Kumbhar, Sujan Piya, Amari M Sockwell, Sami J Morse, Kent Arian and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Krishnan K MahadevanDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ana S MaldonadoDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bingrui LiDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Aaron A BickertDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Adrian Kacperczyk-PerdyanDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shreyasee V KumbharDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sujan PiyaDepartments of Anatomical Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8976-540X
Amari M SockwellDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sami J MorseDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kent ArianDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hikaru SugimotoDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shabnam ShalapourDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-4743-3706
David S HongDepartment of Investigative Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0001-8721-1609
Timothy P HeffernanInsititute for Applied Science and TRACTION platform, University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-3166-8922
Anirban MaitraDepartments of Anatomical Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Raghu KalluriDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. rkalluri@mdanderson.org.ORCID 0000-0002-2190-547X

Funding

The RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2006 to 2025
$41.7M
NCI NIH HHS P01 CA117969U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) NCIP01 CA117969
6 · The paper itself

Abstract

Lack of sustained response to oncogenic Kras (Kras*) inhibition in pancreatic ductal adenocarcinoma (PDAC) underscores the need to identify effective combination therapies. Here, we demonstrate that Kras* targeting using MRTX1133 or Daraxonrasib recruits diverse T-cell infiltrates, including regulatory (Tregs), effector and exhausted T cells into the PDAC microenvironment. Kras* inhibition induces T-cell influx and offers a therapeutic window to specifically prime PDAC to anti-CTLA4 immune checkpoint blockade efficacy, in contrast to anti-PD1, anti-Tim3, anti-Lag3, anti-Vista, and anti-4-1BB agonist combination therapy. Mechanistically, anti-CTLA4 combination therapy transcriptionally reprograms effector Tregs to a naive phenotype, reverses CD8

Indexed as

Carcinoma, Pancreatic DuctalCTLA-4 AntigenPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)AnimalsCD8-Positive T-LymphocytesCell Line, TumorHeterocyclic Compounds, 2-RingHumansImmune Checkpoint InhibitorsMiceNaphthalenesPiperazinesT-Cell ExhaustionT-Lymphocytes, RegulatoryTumor MicroenvironmentCTLA-4 AntigenCTLA4 protein, humandaraxonrasibHeterocyclic Compounds, 2-RingImmune Checkpoint InhibitorsKRASG12D inhibitor MRTX1133KRAS protein, humanNaphthalenesPiperazinesProto-Oncogene Proteins p21(ras)

Identifiers

PMID42649211
PMCPMC13518988

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.